ARDX - Ardelyx, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.05
+0.22 (+3.22%)
As of 3:36PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close6.83
Open6.85
Bid7.08 x 900
Ask7.09 x 1000
Day's Range6.68 - 7.12
52 Week Range2.10 - 8.81
Volume468,410
Avg. Volume769,953
Market Cap627.85M
Beta (5Y Monthly)2.02
PE Ratio (TTM)N/A
EPS (TTM)-1.28
Earnings DateMay 07, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
    PR Newswire

    Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

    Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the submission of a New Drug Application (NDA) for tenapanor to the U.S. Food and Drug Administration (FDA) for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

  • Hedge Funds Are Dumping Ardelyx Inc (ARDX)
    Insider Monkey

    Hedge Funds Are Dumping Ardelyx Inc (ARDX)

    In this article we will take a look at whether hedge funds think Ardelyx Inc (NASDAQ:ARDX) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […]

  • Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
    PR Newswire

    Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today reported positive data from its ongoing NORMALIZE study, which is designed to evaluate the ability of tenapanor, as monotherapy or in combination with sevelamer, to achieve serum phosphorus levels in the normal range (2.5 – 4.5 mg/dL) in patients with chronic kidney disease (CKD) on dialysis. Tenapanor is an investigational, first-in-class, phosphate absorption inhibitor which, if approved, will provide a completely new approach for the control of serum phosphorus in patients with CKD on dialysis, blocking the absorption of phosphorus at the primary pathway of uptake.

  • Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    PR Newswire

    Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that on June 8, 2020, the compensation committee of the Company's Board of Directors granted a non-qualified stock option award to purchase 195,017 shares of its common stock and a restricted stock unit award for 10,000 shares in connection with the commencement of employment of its new Chief Financial Officer, Justin Renz, under the Company's 2016 Employment Commencement Incentive Plan (the "Inducement Plan"). The stock options and restricted stock units were granted as an inducement material to Mr. Renz becoming an employee of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer
    PR Newswire

    Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Justin Renz to the position of Chief Financial Officer. Mr. Renz, a highly accomplished leader with over 20 years of experience in the biopharmaceutical industry, brings an extensive array of financial and operational experience to Ardelyx.

  • Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference
    PR Newswire

    Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 3:00 p.m. ET.

  • Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer
    PR Newswire

    Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Susan Rodriguez, an industry veteran with over 25 years of global pharmaceutical experience, as the company's first chief commercial officer. Ms. Rodriguez will be responsible for leading the commercial organization, including launch planning and strategy, as well as alliance management and business development.

  • Will Ardelyx Continue to Surge Higher?
    Zacks

    Will Ardelyx Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Ardelyx

  • Ardelyx (ARDX) Upgraded to Strong Buy: Here's Why
    Zacks

    Ardelyx (ARDX) Upgraded to Strong Buy: Here's Why

    Ardelyx (ARDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).

  • Analysts Are Upgrading Ardelyx, Inc. (NASDAQ:ARDX) After Its Latest Results
    Simply Wall St.

    Analysts Are Upgrading Ardelyx, Inc. (NASDAQ:ARDX) After Its Latest Results

    As you might know, Ardelyx, Inc. (NASDAQ:ARDX) just kicked off its latest first-quarter results with some very strong...

  • Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights
    PR Newswire

    Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today reported business highlights and financial results for the first quarter ended March 31, 2020.

  • What Did Ardelyx, Inc.'s (NASDAQ:ARDX) CEO Take Home Last Year?
    Simply Wall St.

    What Did Ardelyx, Inc.'s (NASDAQ:ARDX) CEO Take Home Last Year?

    Mike Raab has been the CEO of Ardelyx, Inc. (NASDAQ:ARDX) since 2009. This report will, first, examine the CEO...

  • GlobeNewswire

    Knight Therapeutics Announces Approval of IBSRELA™ in Canada

    MONTREAL, April 17, 2020 -- Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced that Health Canada has approved.

  • Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors
    PR Newswire

    Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors

    Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Onaiza Cadoret-Manier, an industry veteran with deep biopharmaceutical commercial experience, has joined the Company's Board of Directors. Ms. Cadoret-Manier replaces Annalisa Jenkins, who stepped down from the board effective March 12, 2020 in order to be closer and more involved with her Board responsibilities in Europe.

  • Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt
    Simply Wall St.

    Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
    PR Newswire

    Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019.

  • Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference
    PR Newswire

    Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference

    Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the Cowen and Company 40th Annual Health Care Conference at 8:00 a.m. ET on Wednesday, March 4, 2020 in Boston, MA.

  • Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference
    PR Newswire

    Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 3:30 p.m. ET on Wednesday, Feb. 26, 2020 in New York City.

  • How Ardelyx, Inc. (NASDAQ:ARDX) Can Impact Your Portfolio Volatility
    Simply Wall St.

    How Ardelyx, Inc. (NASDAQ:ARDX) Can Impact Your Portfolio Volatility

    If you're interested in Ardelyx, Inc. (NASDAQ:ARDX), then you might want to consider its beta (a measure of share...

  • Benzinga

    The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...

  • Ardelyx Announces Pricing of Upsized Public Offering of Common Stock
    PR Newswire

    Ardelyx Announces Pricing of Upsized Public Offering of Common Stock

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.25 per share, before underwriting discounts and commissions, for gross proceeds of $125,000,000. In addition, Ardelyx has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 3,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about December 9, 2019, subject to customary closing conditions.

  • Ardelyx Announces Proposed Public Offering of Common Stock
    PR Newswire

    Ardelyx Announces Proposed Public Offering of Common Stock

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public offering of up to $80,000,000 of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Ardelyx. In addition, Ardelyx intends to grant the underwriters of the offering the right for a period of 30 days to purchase up to an additional $12,000,000 of shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • Benzinga

    The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares ...

  • Reuters

    UPDATE 2-Ardelyx drug reduces elevated phosphate levels, late-stage study shows

    Ardelyx Inc's experimental drug has shown promise in a late-stage study as a standalone therapy to reduce elevated blood phosphate levels in patients with chronic kidney disease (CKD), the drugmaker said on Tuesday. While investor concern is likely over the higher-than-anticipated discontinuation rate, the results were positive with the drug, tenapanor, hitting the key goal of phosphate lowering, Piper Jaffray analyst Christopher Raymond said. The positive results are the latest in a series of wins for Ardelyx.